Detailed Phenotype of GLA Variants Identified by the Nationwide Neurological Screening of Stroke Patients in the Czech Republic
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic
Document type Journal Article
Grant support
MZCZ-DRO-VFN64165
Ministerstvo Zdravotnictví Ceské Republiky
PubMed
34441839
PubMed Central
PMC8396867
DOI
10.3390/jcm10163543
PII: jcm10163543
Knihovny.cz E-resources
- Keywords
- Fabry disease, GLA gene variants, data sharing, phenotype, screening programs, stroke,
- Publication type
- Journal Article MeSH
Fabry disease (FD) is a rare X-linked disorder of glycosphingolipid metabolism caused by pathogenic variants within the alpha-galactosidase A (GLA) gene, often leading to neurological manifestations including stroke. Multiple screening programs seeking GLA variants among stroke survivors lacked detailed phenotype description, making the interpretation of the detected variant's pathogenicity difficult. Here, we describe detailed clinical characteristics of GLA variant carriers identified by a nationwide stroke screening program in the Czech Republic. A total of 23 individuals with 8 different GLA variants were included in the study. A comprehensive diagnostic workup was performed by a team of FD specialists. The investigation led to the suggestion of phenotype reclassification for the G325S mutation from late-onset to classical. A novel variant R30K was found and was classified as a variant of unknown significance (VUS). The typical manifestation in our FD patients was a stroke occurring in the posterior circulation with an accompanying pathological finding in the cerebrospinal fluid. Moreover, we confirmed that cornea verticillata is typically associated with classical variants. Our findings underline the importance of detailed phenotype description and data sharing in the correct identification of pathogenicity of gene variants detected by high-risk-population screening programs.
Department of Neurology and Stroke Centre Country Hospital Chomutov 430 12 Chomutov Czech Republic
Department of Neurology and Stroke Centre Hospital Karlovy Vary 360 01 Karlovy Vary Czech Republic
Department of Neurology Hospital Ceske Budejovice 370 01 České Budějovice Czech Republic
Institute of Anatomy 1st Faculty of Medicine Charles University Prague 128 08 Prague Czech Republic
See more in PubMed
Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., Laster L. Enzymatic Defect in Fabry’s Disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 1967;276:1163–1167. doi: 10.1056/NEJM196705252762101. PubMed DOI
Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010;5:30. doi: 10.1186/1750-1172-5-30. PubMed DOI PMC
Sweeley C.C., Klionsky B. Fabry’s disease: Classification as a Sphingolipidosis and Partial Characterization of a Novel Glycolipid. J. Biol. Chem. 1963;238:3148–3150. doi: 10.1016/S0021-9258(18)51888-3. PubMed DOI
Elleder M., Dorazilová V., Bradová V., Bĕlohlávek M., Král V., Choura M., Budĕsínský M., Harzer K. Fabry’s disease with isolated disease of the cardiac muscle, manifesting as hypertrophic cardiomyopathy. Cas. Lek. Cesk. 1990;129:369–372. PubMed
Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., Yoshida A., Kuriyama M., Hayashibe H., Sakuraba H., et al. An Atypical Variant of Fabry’s Disease in Men with Left Ventricular Hypertrophy. N. Engl. J. Med. 1995;333:288–293. doi: 10.1056/NEJM199508033330504. PubMed DOI
Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA. 2008;105:2812–2817. doi: 10.1073/pnas.0712309105. PubMed DOI PMC
Arends M., Wanner C., Hughes D., Mehta A., Oder D., Watkinson O.T., Elliott P.M., Linthorst G.E., Wijburg F.A., Biegstraaten M., et al. Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. J. Am. Soc. Nephrol. 2017;28:1631–1641. doi: 10.1681/ASN.2016090964. PubMed DOI PMC
Echevarria L., Benistan K., Toussaint A., Dubourg O., Hagege A.A., Eladari D., Jabbour F., Beldjord C., De Mazancourt P., Germain D.P. X-chromosome inactivation in female patients with Fabry disease. Clin. Genet. 2016;89:44–54. doi: 10.1111/cge.12613. PubMed DOI
Desnick R.J. Chapter 38—Fabry Disease: α-Galactosidase A Deficiency. In: Rosenberg R.N., Pascual J.M., editors. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. 5th ed. Academic Press; Boston, MA, USA: 2015. pp. 419–430.
Chamoles N.A., Blanco M., Gaggioli D. Fabry disease: Enzymatic diagnosis in dried blood spots on filter paper. Clin. Chim. Acta Int. J. Clin. Chem. 2001;308:195–196. doi: 10.1016/S0009-8981(01)00478-8. PubMed DOI
Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., Desnick R.J. High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening. Am. J. Hum. Genet. 2006;79:31–40. doi: 10.1086/504601. PubMed DOI PMC
Doheny D., Srinivasan R., Pagant S., Chen B., Yasuda M., Desnick R.J. Fabry Disease: Prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995–2017. J. Med. Genet. 2018;55:261–268. doi: 10.1136/jmedgenet-2017-105080. PubMed DOI
Ortiz A., Germain D.P., Desnick R.J., Politei J., Mauer M., Burlina A., Eng C., Hopkin R.J., Laney D., Linhart A., et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol. Genet. Metab. 2018;123:416–427. doi: 10.1016/j.ymgme.2018.02.014. PubMed DOI
Fazekas F., Chawluk J.B., Alavi A., Hurtig H.I., Zimmerman R.A. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am. J. Roentgenol. 1987;149:351–356. doi: 10.2214/ajr.149.2.351. PubMed DOI
Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., 3rd, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006. PubMed DOI PMC
Levin A., Stevens P.E., Bilous R.W., Coresh J., De Francisco A.L., De Jong P.E., Griffith K.E., Hemmelgarn B.R., Iseki K., Lamb E.J., et al. Kidney Dissease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 2013;3:1–150.
Mayes J.S., Scheerer J.B., Sifers R.N., Donaldson M.L. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry’s disease. Clin. Chim. Acta Int. J. Clin. Chem. 1981;112:247–251. doi: 10.1016/0009-8981(81)90384-3. PubMed DOI
Palecek T., Honzíková J., Poupetova H., Vlaskova H., Kuchynka P., Goláň L., Magage S., Linhart A. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: Prospective Fabry cardiomyopathy screening study (FACSS) J. Inherit. Metab. Dis. 2014;37:455–460. doi: 10.1007/s10545-013-9659-2. PubMed DOI
Rolfs A., Böttcher T., Zschiesche M., Morris P., Winchester B., Bauer P., Walter U., Mix E., Löhr M., Harzer K., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: A prospective study. Lancet. 2005;366:1794–1796. doi: 10.1016/S0140-6736(05)67635-0. PubMed DOI
International Fabry Disease Genotype-Phenotype Database (dbFGP) [(accessed on 24 November 2020)]; Available online: http://www.dbfgp.org/dbFgp/fabry.
Lukas J., Giese A.K., Markoff A., Grittner U., Kolodny E., Mascher H., Lackner K.J., Meyer W., Wree P., Saviouk V., et al. Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry Disease. PLoS Genet. 2013;9:e1003632. doi: 10.1371/journal.pgen.1003632. PubMed DOI PMC
Lukas J., Cimmaruta C., Liguori L., Pantoom S., Iwanov K., Petters J., Hund C., Bunschkowski M., Hermann A., Cubellis M.V., et al. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease. Int. J. Mol. Sci. 2020;21:956. doi: 10.3390/ijms21030956. PubMed DOI PMC
Kokotis P., Üçeyler N., Werner C., Tsivgoulis G., Papanikola N., Katsanos A.H., Karandreas N., Sommer C. Quantification of sweat gland innervation in patients with Fabry disease: A case-control study. J. Neurol. Sci. 2018;390:135–138. doi: 10.1016/j.jns.2018.04.035. PubMed DOI
Dubost J.J., Viallard I.L., Sauvezie B. Chronic meningitis in Fabry’s disease. J. Neurol. Neurosurg. Psychiatry. 1985;48:714–715. doi: 10.1136/jnnp.48.7.714. PubMed DOI PMC
Uyama E., Ueno N., Uchino M., Narahara T., Owada M., Taketomi T., Ando M. Headache Associated with Aseptic Meningeal Reaction as Clinical Onset of Fabry’s Disease. Headache. 1995;35:498–501. doi: 10.1111/j.1526-4610.1995.hed3508498.x. PubMed DOI
Schreiber W., Udvardi A., Kristoferitsch W. Chronic meningitis and lacunar stroke in Fabry disease. J. Neurol. 2007;254:1447–1449. doi: 10.1007/s00415-007-0533-8. PubMed DOI
Lidove O., Chauveheid M.P., Caillaud C., Froissart R., Benoist L., Alamowitch S., Doan S., Szalat R., Baumann N., Alexandra J.F., et al. Aseptic meningitis and ischaemic stroke in Fabry disease. Int. J. Clin. Pract. 2009;63:1663–1667. doi: 10.1111/j.1742-1241.2009.02115.x. PubMed DOI
Schulte-Mecklenbeck A., Kleffner I., Beuker C., Wirth T., Hartwig M., Schmidt-Pogoda A., Klotz L., Hansen W., Wiendl H., Meuth S.G., et al. Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke. Eur. J. Neurol. 2019;26:919–926. doi: 10.1111/ene.13909. PubMed DOI
Ferreira S., Ortiz A., Germain D.P., Viana-Baptista M., Caldeira-Gomes A., Camprecios M., Fenollar-Cortés M., Gallegos-Villalobos Á., Garcia D., García-Robles J.A., et al. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies. Mol. Genet. Metab. 2015;114:248–258. doi: 10.1016/j.ymgme.2014.11.004. PubMed DOI PMC
Rolfs A., Fazekas F., Grittner U., Dichgans M., Martus P., Holzhausen M., Böttcher T., Heuschmann P.U., Tatlisumak T., Tanislav C., et al. Acute cerebrovascular disease in the young: The Stroke in Young Fabry Patients study. Stroke. 2013;44:340–349. doi: 10.1161/STROKEAHA.112.663708. PubMed DOI
Talbot A., Nicholls K. Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant. JIMD Rep. 2019;45:95–98. doi: 10.1007/8904_2018_146. PubMed DOI PMC
Eng C.M., Ashley G.A., Burgert T.S., Enriquez A.L., D’Souza M., Desnick R.J. Fabry disease: Thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol. Med. 1997;3:174–182. doi: 10.1007/BF03401671. PubMed DOI PMC
Spada M., Marongiu A., Voglino G., Merlino S., Alluto A., La Dolcetta M., Pagliardini S. Molecular Study in 20 unrelated male Patients with Fabry Disease: The A143T genotype correlates with the late-onset end-stage nephropathy (abstract) J. Inherit. Metab. Dis. 2003;26:1–228. doi: 10.1023/A:1024858629434. DOI
Nance C.S., Klein C.J., Banikazemi M., Dikman S.H., Phelps R.G., McArthur J.C., Rodriguez M., Desnick R.J. Later-Onset Fabry Disease: An adult variant presenting with the cramp-fasciculation syndrome. Arch. Neurol. 2006;63:453–457. doi: 10.1001/archneur.63.3.453. PubMed DOI
Shabbeer J., Yasuda M., Benson S.D., Desnick R.J. Fabry disease: Identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum. Genom. 2006;2:297–309. doi: 10.1186/1479-7364-2-5-297. PubMed DOI PMC
Monserrat L., Gimeno-Blanes J.R., Marín F., Hermida-Prieto M., García-Honrubia A., Pérez I., Fernández X., de Nicolas R., de la Morena G., Payá E., et al. Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients with Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2007;50:2399–2403. doi: 10.1016/j.jacc.2007.06.062. PubMed DOI
Lin H.Y., Chong K.W., Hsu J.H., Yu H.C., Shih C.C., Huang C.H., Lin S.J., Chen C.H., Chiang C.C., Ho H.J., et al. High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population. Circ. Cardiovasc. Genet. 2009;2:450–456. doi: 10.1161/CIRCGENETICS.109.862920. PubMed DOI
Corry A., Feighery C., Alderdice D., Stewart F., Walsh M., Dolan O.M. A family with Fabry disease diagnosed by a single angiokeratoma. Dermatol. Online J. 2011;17:5. doi: 10.5070/D35BK233ZQ. PubMed DOI
Wozniak M.A., Kittner S.J., Tuhrim S., Cole J.W., Stern B., Dobbins M., Grace M.E., Nazarenko I., Dobrovolny R., McDade E., et al. Frequency of Unrecognized Fabry Disease Among Young European-American and African-American Men with First Ischemic Stroke. Stroke. 2010;41:78–81. doi: 10.1161/STROKEAHA.109.558320. PubMed DOI PMC
Smid B.E., Hollak C.E., Poorthuis B.J., van den Bergh Weerman M.A., Florquin S., Kok W.E., Lekanne Deprez R.H., Timmermans J., Linthorst G.E. Diagnostic dilemmas in Fabry disease: A case series study on GLA mutations of unknown clinical significance. Clin. Genet. 2015;88:161–166. doi: 10.1111/cge.12449. PubMed DOI
De Brabander I., Yperzeele L., Ceuterick-De Groote C., Brouns R., Baker R., Belachew S., Delbecq J., De Keulenaer G., Dethy S., Eyskens F., et al. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clin. Neurol. Neurosurg. 2013;115:1088–1093. doi: 10.1016/j.clineuro.2012.11.003. PubMed DOI
Hauth L., Kerstens J., Yperzeele L., Eyskens F., Parizel P.M., Willekens B. Galactosidase Alpha p.A143T Variant Fabry Disease May Result in a Phenotype With Multifocal Microvascular Cerebral Involvement at a Young Age. Front. Neurol. 2018;9:336. doi: 10.3389/fneur.2018.00336. PubMed DOI PMC
Lenders M., Weidemann F., Kurschat C., Canaan-Kühl S., Duning T., Stypmann J., Schmitz B., Reiermann S., Krämer J., Blaschke D., et al. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J. Rare Dis. 2016;11:54. doi: 10.1186/s13023-016-0441-z. PubMed DOI PMC
Eng C.M., Resnick-Silverman L.A., Niehaus D.J., Astrin K.H., Desnick R.J. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am. J. Hum. Genet. 1993;53:1186–1197. PubMed PMC
Guffon N., Froissart R., Chevalier-Porst F., Maire I. Mutation analysis in 11 French patients with Fabry disease. Hum. Mutat. 1998;11:S288–S290. doi: 10.1002/humu.1380110190. PubMed DOI
Yasuda M., Shabbeer J., Benson S.D., Maire I., Burnett R.M., Desnick R.J. Fabry disease: Characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum. Mutat. 2003;22:486–492. doi: 10.1002/humu.10275. PubMed DOI
Oder D., Üçeyler N., Liu D., Hu K., Petritsch B., Sommer C., Ertl G., Wanner C., Nordbeck P. Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y. BMJ Open. 2016;6:e010422. doi: 10.1136/bmjopen-2015-010422. PubMed DOI PMC
Niemann M., Rolfs A., Giese A., Mascher H., Breunig F., Ertl G., Wanner C., Weidemann F. Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease. JIMD Rep. 2013;7:99–102. doi: 10.1007/8904_2012_154. PubMed DOI PMC
Hasholt L., Ballegaard M., Bundgaard H., Christiansen M., Law I., Lund A.M., Norremolle A., Krogh Rasmussen A., Ravn K., Tumer Z., et al. The D313Y variant in the GLA gene—No evidence of a pathogenic role in Fabry disease. Scand. J. Clin. Lab. Investig. 2017;77:617–621. doi: 10.1080/00365513.2017.1390782. PubMed DOI
Hadjivassiliou M., Grünewald R.A., Kandler R.H., Chattopadhyay A.K., Jarratt J.A., Sanders D.S., Sharrack B., Wharton S.B., Davies-Jones G.A. Neuropathy associated with gluten sensitivity. J. Neurol. Neurosurg. Psychiatry. 2006;77:1262–1266. doi: 10.1136/jnnp.2006.093534. PubMed DOI PMC
Muehlbacher M., Tripal P., Roas F., Kornhuber J. Identification of Drugs Inducing Phospholipidosis by Novel in vitro Data. ChemMedChem. 2012;7:1925–1934. doi: 10.1002/cmdc.201200306. PubMed DOI PMC
Grassi S., Chiricozzi E., Mauri L., Sonnino S., Prinetti A. Sphingolipids and neuronal degeneration in lysosomal storage disorders. J. Neurochem. 2019;148:600–611. doi: 10.1111/jnc.14540. PubMed DOI
Askari H., Kaneski C.R., Semino-Mora C., Desai P., Ang A., Kleiner D.E., Perlee L.T., Quezado M., Spollen L.E., Wustman B.A., et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Archiv. 2007;451:823–834. doi: 10.1007/s00428-007-0468-6. PubMed DOI
Zotter A., Bäuerle F., Dey D., Kiss V., Schreiber G. Quantifying enzyme activity in living cells. J. Biol. Chem. 2017;292:15838–15848. doi: 10.1074/jbc.M117.792119. PubMed DOI PMC
Koulousios K., Stylianou K., Pateinakis P., Zamanakou M., Loules G., Manou E., Kyriklidou P., Katsinas C., Ouzouni A., Kyriazis J., et al. Fabry disease due to D313Y and novel GLA mutations. BMJ Open. 2017;7:e017098. doi: 10.1136/bmjopen-2017-017098. PubMed DOI PMC
Chew E., Ghosh M., McCulloch C. Amiodarone-induced cornea verticillata. Can. J. Ophthalmol. 1982;17:96–99. PubMed
Raizman M.B., Hamrah P., Holland E.J., Kim T., Mah F.S., Rapuano C.J., Ulrich R.G. Drug-induced corneal epithelial changes. Surv. Ophthalmol. 2017;62:286–301. doi: 10.1016/j.survophthal.2016.11.008. PubMed DOI
Van Der Tol L., Cassiman D., Houge G., Janssen M.C., Lachmann R.H., Linthorst G.E., Ramaswami U., Sommer C., Tøndel C., West M.L., et al. Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up. JIMD Rep. 2014;17:83–90. doi: 10.1007/8904_2014_342. PubMed DOI PMC
Missed diagnosis of Fabry disease: should we screen patients with multiple sclerosis?
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
